John Hertig, PharmD, MS CPPS, FASHP, FFIP

State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.